-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

Benzinga·03/12/2025 14:32:39
Listen to the news
Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and maintains $8 price target.